SEC Form 4 · accession 0001178913-18-000722
Foamix Pharmaceuticals Ltd. · FOMX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Yohan Hazot
Officer — VP Pharmaceutical Development
Period of report
Feb 27, 2018
Accepted (ET)
Feb 28, 2018 · 4:09 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001606645
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF2,F1 | Feb 27, 2018 | A | 5,000 | $0.00 | A | 32,300 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| OptionsF3,F4 | $6.40 | Feb 27, 2018 | A | 15,000 | A | — | Feb 27, 2028 | Ordinary Shares | 15,000 | 15,000 | D |
Explanation of responses
- F1This security represents restricted share units. Each restricted share unit represents a contingent right to receive one ordinary share of the issuer.
- F2The ordinary shares underlying this restricted share unit award vest over a period of four years (25% on February 27, 2019 and 6.25% every three months thereafter) ending February 27, 2022.
- F3Each option represents a contingent right to purchase one ordinary share of the issuer.
- F4The ordinary shares underlying these options vest over a period of four years (25% on February 27, 2019 and 6.25% every three months thereafter) ending February 27, 2022.